AYTU Aytu BioPharma, Inc.
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hype…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 Aytu BioPharma, Inc. Q4 2026 Earnings Call Summary Moby summary of Aytu BioPharma, Inc.'s Q4 2026 earnings call | ||
Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ... Aytu BioPharma Inc (AYTU) posted $16.1 million in Q4 FY2026 revenue as EXXUA prescriptions surged 138% and the company swung to positive adjusted EBITDA of $0.5 million. | ||
 Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of +77.27% and +39.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates HeartSciences Inc. (HSCS) delivered earnings and revenue surprises of -10.26% and -97.90%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 New Strong Sell Stocks for July 20th ACR, AEM and AYTU have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2026. | ||
 New Strong Sell Stocks for July 16th AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026. | ||